Laboratory studies on animal models showed that the Gal-3 induced deficiency may reduce the severity of multiple sclerosis, suggesting that Gal-3 plays an important pathogenic role in multiple sclerosis and could be a therapeutic target for autoimmune demyelinating diseases [91]. Here, LGALS3 is linked to multiple sclerosis.